HRP20110226T1 - Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora - Google Patents
Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora Download PDFInfo
- Publication number
- HRP20110226T1 HRP20110226T1 HR20110226T HRP20110226T HRP20110226T1 HR P20110226 T1 HRP20110226 T1 HR P20110226T1 HR 20110226 T HR20110226 T HR 20110226T HR P20110226 T HRP20110226 T HR P20110226T HR P20110226 T1 HRP20110226 T1 HR P20110226T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorder
- disorders
- compound
- hydrogen
- compound according
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- CKODDUILXBOSEM-UHFFFAOYSA-N n-piperidin-4-ylpyridazin-3-amine Chemical class C1CNCCC1NC1=CC=CN=N1 CKODDUILXBOSEM-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 239000001257 hydrogen Substances 0.000 claims abstract 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract 8
- 150000002367 halogens Chemical group 0.000 claims abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 125000001544 thienyl group Chemical group 0.000 claims abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 150000002431 hydrogen Chemical group 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 10
- 208000028017 Psychotic disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 239000007810 chemical reaction solvent Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- -1 3,4-difluorophenyl Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000021465 Brief psychotic disease Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- UOLHGUUKFNZTNS-UHFFFAOYSA-N N-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine dihydrochloride Chemical compound Cl.Cl.Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F UOLHGUUKFNZTNS-UHFFFAOYSA-N 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 208000030988 Schizoid Personality disease Diseases 0.000 claims 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 239000003377 acid catalyst Substances 0.000 claims 1
- 230000037328 acute stress Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ZYTQDEZEZPUVHY-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine Chemical compound C1=CC(F)=CC=C1CN1CCC(NC=2N=NC(=CC=2)C(F)(F)F)CC1 ZYTQDEZEZPUVHY-UHFFFAOYSA-N 0.000 claims 1
- 208000024817 paranoid personality disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110028 | 2005-10-26 | ||
| EP06100209 | 2006-01-10 | ||
| EP06101545 | 2006-02-10 | ||
| PCT/EP2006/067696 WO2007048779A1 (en) | 2005-10-26 | 2006-10-24 | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110226T1 true HRP20110226T1 (hr) | 2011-05-31 |
Family
ID=35734993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110226T HRP20110226T1 (hr) | 2005-10-26 | 2011-03-29 | Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US8940743B2 (es) |
| EP (1) | EP1943242B1 (es) |
| JP (1) | JP5140598B2 (es) |
| KR (1) | KR101351910B1 (es) |
| CN (1) | CN101291925B (es) |
| AP (1) | AP2607A (es) |
| AR (1) | AR058151A1 (es) |
| AT (1) | ATE495167T1 (es) |
| AU (1) | AU2006307930B2 (es) |
| BR (1) | BRPI0617787A2 (es) |
| CA (1) | CA2623160C (es) |
| CR (1) | CR10020A (es) |
| CY (1) | CY1111977T1 (es) |
| DE (1) | DE602006019624D1 (es) |
| DK (1) | DK1943242T3 (es) |
| EA (1) | EA015681B1 (es) |
| EC (1) | ECSP088396A (es) |
| ES (1) | ES2359020T3 (es) |
| GT (1) | GT200800033A (es) |
| HK (1) | HK1124317A1 (es) |
| HN (1) | HN2008000646A (es) |
| HR (1) | HRP20110226T1 (es) |
| IL (1) | IL191016A (es) |
| JO (1) | JO2769B1 (es) |
| MY (1) | MY145609A (es) |
| NO (1) | NO20082350L (es) |
| NZ (1) | NZ566785A (es) |
| PL (1) | PL1943242T3 (es) |
| PT (1) | PT1943242E (es) |
| RS (1) | RS51674B (es) |
| SI (1) | SI1943242T1 (es) |
| TW (1) | TWI399373B (es) |
| UA (1) | UA94058C2 (es) |
| WO (1) | WO2007048779A1 (es) |
| ZA (1) | ZA200803668B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| JO2642B1 (en) * | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| CN101663292A (zh) * | 2007-04-23 | 2010-03-03 | 詹森药业有限公司 | 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物 |
| AU2008240727C1 (en) * | 2007-04-23 | 2013-10-03 | Janssen Pharmaceutica N.V. | Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists |
| CA2682671C (en) | 2007-04-23 | 2015-11-17 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| US8653262B2 (en) | 2007-05-31 | 2014-02-18 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists and uses thereof |
| CN102159554B (zh) | 2008-07-03 | 2014-09-24 | 詹森药业有限公司 | 作为5-ht6受体拮抗剂的取代的6-(1-哌嗪基)-哒嗪 |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| LT2307374T (lt) | 2008-07-31 | 2017-04-25 | Janssen Pharmaceutica Nv | Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai |
| PL2379525T3 (pl) | 2008-12-19 | 2016-01-29 | Centrexion Therapeutics Corp | Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD |
| CA2778949C (en) | 2009-10-30 | 2018-02-27 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors |
| JP5632014B2 (ja) | 2009-12-17 | 2014-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト及びこれらの使用 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
| EP2723744B1 (en) | 2011-06-27 | 2016-03-23 | Janssen Pharmaceutica, N.V. | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
| CA2875057C (en) | 2012-07-09 | 2021-07-13 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme |
| WO2017004537A1 (en) | 2015-07-02 | 2017-01-05 | Centrexion Therapeutics Corporation | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
| US20180350708A1 (en) * | 2017-06-06 | 2018-12-06 | Powertech Technology Inc. | Package structure and manufacturing method thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3933823A (en) * | 1971-03-29 | 1976-01-20 | E. R. Squibb & Sons, Inc. | Isoxazolopyridine ketone derivatives |
| DE2341965C3 (de) * | 1973-08-20 | 1979-01-25 | C.H. Boehringer Sohn, 6507 Ingelheim | 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen |
| NO147672C (no) | 1975-09-23 | 1983-05-25 | Janssen Pharmaceutica Nv | Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider |
| US4197304A (en) * | 1975-09-23 | 1980-04-08 | Janssen Pharmaceutica N.V. | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides |
| EG12406A (en) * | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
| DE3218482A1 (de) * | 1982-05-15 | 1983-11-17 | Bayer Ag, 5090 Leverkusen | Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| ES8802151A1 (es) | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
| MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US5461053A (en) * | 1989-02-07 | 1995-10-24 | Sanofi | Pyridazine derivatives |
| PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
| GB9008850D0 (en) * | 1990-04-19 | 1990-06-13 | Janssen Pharmaceutica Nv | Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones |
| GB9216298D0 (en) | 1991-08-15 | 1992-09-16 | Ici Plc | Piperidine derivatives |
| ES2133714T3 (es) | 1993-12-28 | 1999-09-16 | Upjohn Co | Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares. |
| DE4425145A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung von Thiazol- und Thiadiazolverbindungen |
| TW406075B (en) * | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
| US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5753679A (en) | 1995-05-10 | 1998-05-19 | Hoffmann-La Roche Inc. | Benzyl-piperidine derivatives |
| MY116093A (en) * | 1996-02-26 | 2003-11-28 | Upjohn Co | Azolyl piperazinyl phenyl oxazolidinone antimicrobials |
| TW504510B (en) | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| ID23803A (id) * | 1997-08-15 | 2000-05-11 | Pfizer Prod Inc | Turunan-turunan 2-(4-aril atau heteroaril-piperazin-1-ilmetil)-1h-indola |
| KR100261139B1 (ko) | 1998-01-16 | 2000-08-01 | 황준수 | 신규한 알릴티오피리다진 유도체 및 그의 제조방법 |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| KR100849839B1 (ko) | 2001-02-23 | 2008-08-01 | 머크 앤드 캄파니 인코포레이티드 | Ｎ-치환된 비-아릴-헤테로사이클릭 ｎｍｄａ/ｎｒ2ｂ 길항제 및 이를 포함하는 약제학적 조성물 |
| KR100938369B1 (ko) | 2001-10-09 | 2010-01-22 | 교린 세이야꾸 가부시키 가이샤 | 신규 4-(2-푸로일)아미노피페리딘, 그의 합성 중간체,그의 제조방법 및 의약으로서의 그의 용도 |
| GB0127832D0 (en) | 2001-11-20 | 2002-01-09 | Jagotec Ag | Method for the preparation of pharmaceutical nanosuspensions |
| US7812035B2 (en) | 2001-12-11 | 2010-10-12 | Sepracor Inc. | 4-substituted piperidines, and methods of use thereof |
| WO2003062215A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| EP1474401A2 (en) | 2002-02-05 | 2004-11-10 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
| US20030236259A1 (en) | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
| WO2003072548A1 (en) | 2002-02-22 | 2003-09-04 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
| SE0201544D0 (sv) | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
| JP3625214B2 (ja) * | 2002-09-26 | 2005-03-02 | 株式会社マンダム | 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品 |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| RU2344128C2 (ru) | 2003-03-24 | 2009-01-20 | Ф.Хоффманн-Ля Рош Аг | Бензилпиридазиноны как ингибиторы обратной транскриптазы |
| DE50312980D1 (de) * | 2003-05-07 | 2010-09-23 | Kemira Pigments Oy | Ftstoffen und aromen |
| JP4009303B2 (ja) | 2003-05-08 | 2007-11-14 | 杏林製薬株式会社 | 掻痒治療薬として有用な４−（２−フロイル）アミノピペリジン類 |
| WO2005005779A2 (en) | 2003-07-14 | 2005-01-20 | Genesis Mining Technologies (Pty) Ltd | Dual retention cutting arrangement |
| AU2004259263B2 (en) | 2003-07-29 | 2010-12-16 | High Point Pharmaceuticals, Llc | Pyridazinyl- piperazines and their use as histamine H3 receptor ligands |
| WO2005011655A2 (en) * | 2003-07-30 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| JP2007501801A (ja) | 2003-08-07 | 2007-02-01 | 日本たばこ産業株式会社 | ピロロ［１，２−ｂ］ピリダジン誘導体 |
| US7863044B2 (en) | 2003-10-24 | 2011-01-04 | Tao Cheng | p18 in stem cell manipulations |
| BRPI0506676A (pt) | 2004-02-10 | 2007-05-15 | Janssen Phamaceutica N V | piridazinona uréias como antagonistas de integrinas alfa4 |
| CN1934092A (zh) | 2004-03-23 | 2007-03-21 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
| BRPI0510340A (pt) | 2004-04-28 | 2007-10-30 | Pfizer | derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina |
| EP1753429A1 (en) | 2004-05-28 | 2007-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| CA2585172C (en) | 2004-10-29 | 2014-08-12 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of ppar |
| JP2008534640A (ja) * | 2005-04-05 | 2008-08-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | タンパク質の機能部位またはエピトープの遮蔽方法 |
| CN101243072A (zh) | 2005-06-20 | 2008-08-13 | 先灵公司 | 用作组胺h3拮抗剂的哌啶衍生物 |
| JO2769B1 (en) * | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| CN101506165B (zh) | 2006-08-15 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | 苯基、吡啶和喹啉衍生物 |
| CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| JO2642B1 (en) * | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| AU2008240727C1 (en) * | 2007-04-23 | 2013-10-03 | Janssen Pharmaceutica N.V. | Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists |
| CA2682671C (en) * | 2007-04-23 | 2015-11-17 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| CN101663292A (zh) * | 2007-04-23 | 2010-03-03 | 詹森药业有限公司 | 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物 |
| AR068480A1 (es) * | 2007-09-20 | 2009-11-18 | Glaxo Group Ltd | Compuesto de 4-heteroaril-piperidinil-n-substituido su uso para la preparacion de un medicamento util para el tratamiento de una afeccion en el que seria beneficioso el agonismo de un receptor muscarinico m1 y composicion farmaceutica que lo comprende |
| CN102159554B (zh) * | 2008-07-03 | 2014-09-24 | 詹森药业有限公司 | 作为5-ht6受体拮抗剂的取代的6-(1-哌嗪基)-哒嗪 |
| LT2307374T (lt) | 2008-07-31 | 2017-04-25 | Janssen Pharmaceutica Nv | Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai |
-
2006
- 2006-10-12 JO JO2006368A patent/JO2769B1/en active
- 2006-10-24 KR KR1020087011462A patent/KR101351910B1/ko active IP Right Grant
- 2006-10-24 WO PCT/EP2006/067696 patent/WO2007048779A1/en active Application Filing
- 2006-10-24 DK DK06807495.4T patent/DK1943242T3/da active
- 2006-10-24 PL PL06807495T patent/PL1943242T3/pl unknown
- 2006-10-24 ES ES06807495T patent/ES2359020T3/es active Active
- 2006-10-24 NZ NZ566785A patent/NZ566785A/en not_active IP Right Cessation
- 2006-10-24 RS RS20110153A patent/RS51674B/en unknown
- 2006-10-24 PT PT06807495T patent/PT1943242E/pt unknown
- 2006-10-24 CN CN2006800389935A patent/CN101291925B/zh active Active
- 2006-10-24 AU AU2006307930A patent/AU2006307930B2/en not_active Ceased
- 2006-10-24 US US12/091,219 patent/US8940743B2/en active Active
- 2006-10-24 EA EA200801184A patent/EA015681B1/ru unknown
- 2006-10-24 BR BRPI0617787-5A patent/BRPI0617787A2/pt not_active IP Right Cessation
- 2006-10-24 CA CA2623160A patent/CA2623160C/en not_active Expired - Fee Related
- 2006-10-24 AT AT06807495T patent/ATE495167T1/de active
- 2006-10-24 UA UAA200803291A patent/UA94058C2/ru unknown
- 2006-10-24 DE DE602006019624T patent/DE602006019624D1/de active Active
- 2006-10-24 EP EP06807495A patent/EP1943242B1/en active Active
- 2006-10-24 SI SI200630966T patent/SI1943242T1/sl unknown
- 2006-10-24 MY MYPI20081298A patent/MY145609A/en unknown
- 2006-10-24 AP AP2008004441A patent/AP2607A/xx active
- 2006-10-24 JP JP2008537078A patent/JP5140598B2/ja active Active
- 2006-10-25 AR ARP060104659A patent/AR058151A1/es unknown
- 2006-10-25 TW TW095139268A patent/TWI399373B/zh not_active IP Right Cessation
-
2008
- 2008-03-31 GT GT200800033A patent/GT200800033A/es unknown
- 2008-04-23 EC EC2008008396A patent/ECSP088396A/es unknown
- 2008-04-23 HN HN2008000646A patent/HN2008000646A/es unknown
- 2008-04-25 ZA ZA200803668A patent/ZA200803668B/xx unknown
- 2008-04-27 IL IL191016A patent/IL191016A/en active IP Right Grant
- 2008-05-26 CR CR10020A patent/CR10020A/es unknown
- 2008-05-26 NO NO20082350A patent/NO20082350L/no not_active Application Discontinuation
-
2009
- 2009-02-11 HK HK09101264.8A patent/HK1124317A1/xx not_active IP Right Cessation
-
2011
- 2011-03-29 HR HR20110226T patent/HRP20110226T1/hr unknown
- 2011-04-12 CY CY20111100375T patent/CY1111977T1/el unknown
-
2015
- 2015-01-26 US US14/605,873 patent/US9468640B2/en active Active
-
2016
- 2016-09-13 US US15/264,185 patent/US9751860B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110226T1 (hr) | Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora | |
| HRP20120913T1 (hr) | Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| HRP20100121T1 (hr) | Derivati n-(aminoheteroaril)-1h-indol-2-karboksamida, njihovo dobivanje i terapijska primjena | |
| AR035979A1 (es) | Derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y usos de dichos compuestos para la preparacion de medicament0s | |
| HRP20170570T1 (hr) | Piperazin-1-il-trifluormetil-supstituirani-piridini kao brzo disocirajući antagonisti receptora dopamina 2 | |
| NZ593295A (en) | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor | |
| HRP20130984T1 (hr) | Spoj aciltiouree ili njegove soli, i njegova primjena | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| US20190389865A1 (en) | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| HRP20120166T1 (hr) | Supstituirane n-bipirolidinuree i njihova upotreba u terapiji | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| RU2010108943A (ru) | Новые пиперазинамидные производные | |
| JP2004532823A5 (es) | ||
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| RU2011103759A (ru) | Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора | |
| TW200833697A (en) | Spiro-piperidine derivatives | |
| TW402601B (en) | Aminocycloalkylpyrrolidinyl-substituted quinolone derivatives having antibacterial effect and pharmaceutical composition containing them | |
| TW200616635A (en) | Novel compounds | |
| RU2009142981A (ru) | Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2 | |
| HUP0303751A2 (hu) | N-fenil-pirimidin-amin-származékok alkalmazása hízósejt alapú betegségekhez hasonló allergiás rendellenességek kezelésére alkalmas gyógyszerkészítmények előállítására | |
| HRP20120344T1 (hr) | N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije | |
| MX2009005544A (es) | Indoles. | |
| RU2009142988A (ru) | Производные пиридина, используемые в качестве быстро диссоциирующихся антагонистов допаминовых рецепторов 2 | |
| GEP20115240B (en) | Indole derivatives, process for their preparation and pharmaceutical compositions containing them |